World News 360
Sunday, 30 August 2020
ESC: AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook - FiercePharma
ESC: AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook
FiercePharma
View Full Coverage on Google News
from Business - Latest - Google News https://ift.tt/2YOit89
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment